Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 2171100Generated: November 2, 2026

Cesium carbonate → 5(4-(Difluoromethoxy)-2-isobutoxy-3-methoxyphenyl)isoindolin-1-one

https://huagongshe.com/reaction/2171100

Reaction equation

Participants

RoleNameHCIDCharge
ReactantCesium carbonateHCID 10796—
Reactant5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-oneHCID 21955795—
Reactant1-Bromo-4-(difluoromethoxy)-2-isobutoxy-3-methoxybenzeneHCID 67465506—
CatalystTetrakis(triphenylphosphine)palladiumHCID 11979704—
SolventDimethylformamideHCID 6228—
Product5(4-(Difluoromethoxy)-2-isobutoxy-3-methoxyphenyl)isoindolin-1-oneHCID 67467831—

Reaction Conditions

Temperature85 °C

Reaction Steps

To a stirring solution of 6-bromo-3-(difluoromethoxy)-2-methoxyphenol (100 mg, 0.371 mmol) in acetonitrile (10 mL), was added potassium carbonate (153.8 mg, 1.114 mmol) and isobutyl bromide (152.6 mg, 1.114 mmol) and the resultant reaction mixture was heated to 80° C. for 3 h. The reaction mixture was cooled to RT, filtered through celite and the filtrate was concentrated under reduced pressure to afford 300 mg of 1-Bromo-4-(difluoromethoxy)-2-isobutoxy-3-methoxybenzene as a solid. To a stirring solution of 1-bromo-4-(difluoromethoxy)-2-isobutoxy-3-methoxybenzene (200 mg, 0.615 mmol) in dimethylformamide (5 mL) was purged with argon for 1 h. To this cesium carbonate (599 mg, 1.84 mmol), tetrakis(triphenylphosphine) palladium(0) (35 mg, 0.030 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (191 mg, 0.738 mmol) were added and the resultant reaction mixture was heated to 80-90° C. for 3 h. The reaction mixture was cooled to RT, filtered and the filtrate was diluted with water and extracted with ethyl acetate (3×). The combined ethyl acetate layer was washed with brine and dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel, 0-20% ethyl acetate in pet ether) afforded the title compound as a (30 mg, 13%).

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS09051290B2
Source datasetuspto-grants-2015_06
ORD IDord-e17c5acec0504c169f0e5946c8e81316
Source noteuspto-grants-2015_06